MX2021012541A - Supervision de la terapia genica. - Google Patents

Supervision de la terapia genica.

Info

Publication number
MX2021012541A
MX2021012541A MX2021012541A MX2021012541A MX2021012541A MX 2021012541 A MX2021012541 A MX 2021012541A MX 2021012541 A MX2021012541 A MX 2021012541A MX 2021012541 A MX2021012541 A MX 2021012541A MX 2021012541 A MX2021012541 A MX 2021012541A
Authority
MX
Mexico
Prior art keywords
gene therapy
technologies
monitoring gene
things
present disclosure
Prior art date
Application number
MX2021012541A
Other languages
English (en)
Inventor
B Nelson Chau
Jing Liao
Susana Gordo
Original Assignee
Logicbio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Logicbio Therapeutics Inc filed Critical Logicbio Therapeutics Inc
Publication of MX2021012541A publication Critical patent/MX2021012541A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona, entre otras cosas, tecnologías para mejorar la terapia génica. Entre otras cosas, la presente descripción proporciona tecnologías que permiten la supervisión y/o evaluación de una o más características de un tratamiento por terapia génica tales como, por ejemplo, el grado, el nivel y/o la persistencia de la expresión de la carga activa. En algunas modalidades, se proporcionan tecnologías particularmente útiles con la terapia génica integradora.
MX2021012541A 2019-04-15 2020-04-14 Supervision de la terapia genica. MX2021012541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833875P 2019-04-15 2019-04-15
PCT/US2020/028102 WO2020214582A1 (en) 2019-04-15 2020-04-14 Monitoring gene therapy

Publications (1)

Publication Number Publication Date
MX2021012541A true MX2021012541A (es) 2021-11-12

Family

ID=72837570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012541A MX2021012541A (es) 2019-04-15 2020-04-14 Supervision de la terapia genica.

Country Status (13)

Country Link
US (1) US20220308070A1 (es)
EP (1) EP3955972A4 (es)
JP (1) JP2022529433A (es)
KR (1) KR20220021906A (es)
CN (1) CN114072181A (es)
AU (1) AU2020258371A1 (es)
BR (1) BR112021020499A2 (es)
CA (1) CA3135666A1 (es)
IL (1) IL287186A (es)
MA (1) MA55727A (es)
MX (1) MX2021012541A (es)
SG (1) SG11202110584TA (es)
WO (1) WO2020214582A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632800B1 (en) * 1999-08-17 2003-10-14 Mayo Foundation For Medical Education And Research System for monitoring the expression of transgenes
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20090247475A1 (en) * 2004-03-05 2009-10-01 The Regents Of The University Of California Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies
WO2015143177A1 (en) * 2014-03-21 2015-09-24 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
US20220218843A1 (en) * 2018-08-10 2022-07-14 Logicbio Therapeutics, Inc. Non-disruptive gene therapy for the treatment of mma

Also Published As

Publication number Publication date
MA55727A (fr) 2022-02-23
EP3955972A4 (en) 2023-01-11
CA3135666A1 (en) 2020-10-22
US20220308070A1 (en) 2022-09-29
AU2020258371A1 (en) 2021-10-28
SG11202110584TA (en) 2021-10-28
WO2020214582A1 (en) 2020-10-22
BR112021020499A2 (pt) 2021-12-07
IL287186A (en) 2021-12-01
KR20220021906A (ko) 2022-02-22
EP3955972A1 (en) 2022-02-23
CN114072181A (zh) 2022-02-18
JP2022529433A (ja) 2022-06-22

Similar Documents

Publication Publication Date Title
ZA201805009B (en) Stable inoculant compositions and methods for producing same
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
WO2015168149A3 (en) Sensorineural hair cell differentiation
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
MX2015015564A (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
WO2018236995A3 (en) METHODS FOR MODULATING REGULATORY T LYMPHOCYTES, REGULATORY B LYMPHOCYTES AND IMMUNE RESPONSES USING AVRIL-TACI INTERACTION MODULATORS
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
PH12021550558A1 (en) Modulators of pnpla3 expression
EP4378535A3 (en) Antibiotic formulations for lower back pain
AU2018337668A1 (en) Improved supraparticles
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2021014206A (es) Oligonucleotidos gapmer modificados y metodos de uso.
JOP20200291A1 (ar) معدلات التعبير عن apol1
MX2020009147A (es) Moduladores de la expresion de irf4.
CA3063204A1 (en) Clotting factor variants and their use
MX2019006552A (es) Terapia génica para mucopolisacaridosis de tipo i.
JOP20210108A1 (ar) معدِّلات تعبير irf5
MX2021012541A (es) Supervision de la terapia genica.
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EP4220176A3 (en) Biomarkers
MX2019013785A (es) Metodos y tratamiento de trauma.
MX2019011761A (es) Dispersion de polímero acuosa y composición de recubrimiento acuosa que la comprende.